GLENMARKPharmaceuticals
Glenmark Pharmaceuticals Ltd — Profit & Loss Statement
₹2131.70
+0.82%
Glenmark Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -93.81 Cr | -270.29 Cr | -231.95 Cr | -83.04 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.30 | 0.30 | 0.31 | — |
| Normalized EBITDA | 2.47K Cr | 2.08K Cr | 1.97K Cr | 2.49K Cr | — |
| Total Unusual Items | -372.82 Cr | -900.96 Cr | -773.17 Cr | -267.38 Cr | — |
| Total Unusual Items Excluding Goodwill | -372.82 Cr | -900.96 Cr | -773.17 Cr | -267.38 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 1.05K Cr | -1.90K Cr | -169.72 Cr | 941.71 Cr | — |
| Reconciled Depreciation | 486.01 Cr | 630.81 Cr | 611.27 Cr | 486.71 Cr | — |
| Reconciled Cost Of Revenue | 4.35K Cr | 4.41K Cr | 4.59K Cr | 4.78K Cr | — |
| EBITDA | 2.09K Cr | 1.18K Cr | 1.20K Cr | 2.23K Cr | — |
| EBIT | 1.61K Cr | 552.46 Cr | 588.88 Cr | 1.74K Cr | — |
| Net Interest Income | -207.06 Cr | -515.97 Cr | -342.04 Cr | -288.66 Cr | — |
| Interest Expense | 207.06 Cr | 515.97 Cr | 349.04 Cr | 298.10 Cr | — |
| Normalized Income | 1.33K Cr | -1.27K Cr | 371.50 Cr | 1.13K Cr | — |
| Net Income From Continuing And Discontinued Operation | 1.05K Cr | -1.50K Cr | 297.25 Cr | 941.71 Cr | — |
| Total Expenses | 11.28K Cr | 11.02K Cr | 10.35K Cr | 10.33K Cr | — |
| Diluted Average Shares | 28.22 Cr | 28.22 Cr | 28.22 Cr | 28.22 Cr | — |
| Basic Average Shares | 28.22 Cr | 28.22 Cr | 28.22 Cr | 28.22 Cr | — |
| Diluted EPS | 37.11 | -53.22 | 10.53 | 33.37 | — |
| Basic EPS | 37.11 | -53.22 | 10.53 | 33.37 | — |
| Diluted NI Availto Com Stockholders | 1.05K Cr | -1.50K Cr | 297.25 Cr | 941.71 Cr | — |
| Net Income Common Stockholders | 1.05K Cr | -1.50K Cr | 297.25 Cr | 941.71 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 1.05K Cr | -1.50K Cr | 297.25 Cr | 941.71 Cr | — |
| Minority Interests | -0.04 Cr | -68.15 Cr | -80.16 Cr | -51.94 Cr | — |
| Net Income Including Noncontrolling Interests | 1.05K Cr | -1.43K Cr | 377.40 Cr | 993.65 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 397.33 Cr | 466.96 Cr | — | — |
| Net Income Continuous Operations | 1.05K Cr | -1.83K Cr | -89.56 Cr | 993.65 Cr | — |
| Tax Provision | 352.07 Cr | 1.87K Cr | 329.40 Cr | 447.60 Cr | — |
| Pretax Income | 1.40K Cr | 36.49 Cr | 239.84 Cr | 1.44K Cr | — |
| Other Non Operating Income Expenses | 113.72 Cr | 839.99 Cr | 72.33 Cr | 68.83 Cr | — |
| Special Income Charges | -372.82 Cr | -900.96 Cr | -773.17 Cr | -267.38 Cr | — |
| Other Special Charges | 175.00 Cr | 900.96 Cr | 760.13 Cr | 6.46 Cr | — |
| Restructuring And Mergern Acquisition | 197.82 Cr | — | — | — | — |
| Net Non Operating Interest Income Expense | -207.06 Cr | -515.97 Cr | -342.04 Cr | -288.66 Cr | — |
| Interest Expense Non Operating | 207.06 Cr | 515.97 Cr | 349.04 Cr | 298.10 Cr | — |
| Operating Income | 1.87K Cr | 613.42 Cr | 1.08K Cr | 1.84K Cr | — |
| Operating Expense | 6.93K Cr | 6.61K Cr | 5.77K Cr | 5.56K Cr | — |
| Other Operating Expenses | 3.59K Cr | 3.34K Cr | 1.16K Cr | 1.26K Cr | — |
| Depreciation And Amortization In Income Statement | 486.01 Cr | 581.91 Cr | 569.17 Cr | 486.71 Cr | — |
| Depreciation Income Statement | 486.01 Cr | 581.91 Cr | 569.17 Cr | 486.71 Cr | — |
| Gross Profit | 8.79K Cr | 7.22K Cr | 6.85K Cr | 7.40K Cr | — |
| Cost Of Revenue | 4.35K Cr | 4.41K Cr | 4.59K Cr | 4.78K Cr | — |
| Total Revenue | 13.15K Cr | 11.64K Cr | 11.43K Cr | 12.17K Cr | — |
| Operating Revenue | 13.15K Cr | 11.64K Cr | 11.43K Cr | 12.17K Cr | — |
| Interest Income | — | 6.18 Cr | 7.00 Cr | 9.44 Cr | 2.65 Cr |
| Rent Expense Supplemental | — | 62.61 Cr | 55.60 Cr | 35.35 Cr | 37.90 Cr |
| Write Off | — | 17.65 Cr | 13.04 Cr | 0.00 | — |
| Impairment Of Capital Assets | — | -1.10K Cr | — | 260.91 Cr | — |
| Interest Income Non Operating | — | 6.18 Cr | 7.00 Cr | 9.44 Cr | 2.65 Cr |
| Selling General And Administration | — | 1.36K Cr | 1.43K Cr | 1.30K Cr | 1.26K Cr |
| Selling And Marketing Expense | — | 1.09K Cr | 1.14K Cr | 896.31 Cr | 943.21 Cr |
| General And Administrative Expense | — | 263.11 Cr | 294.85 Cr | 400.70 Cr | 317.26 Cr |
| Rent And Landing Fees | — | 62.61 Cr | 55.60 Cr | 35.35 Cr | 37.90 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Glenmark Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.